XTalks

JANUARY 20, 2021

Researchers at KU Leuven in Belgium have found a potential mechanism underlying irritable bowel syndrome (IBS) that involves activation of immune cells primed by past gastrointestinal infections. However, IBS patients do not have allergies to any given foods, nor any gastrointestinal conditions, such as celiac disease.

Immune Response 52

Immune Response Research Allergies Protein 52

Scienmag

JUNE 3, 2021

New research into Alzheimer’s disease (AD) suggests that secondary infections and new inflammatory events amplify the brain’s immune response and affect memory in mice and in humans – even when these secondary events occur outside the brain.

Immune Response 41

Immune Response Scientist Research Allergies 41

Scienmag

DECEMBER 16, 2020

Scientists at the Ragon Institute of MGH, MIT and Harvard find that neutralizing antibody potency predicts severe or fatal COVID-19. BOSTON — Understanding the body’s immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines.

Antibody 40

Antibody Immune Response Scientist Vaccination 40

The Pharma Data

MARCH 13, 2022

That’s because the mutations that led to the variant’s emergence aren’t found in the regions of the virus that stimulates one type of cellular immune response, says an international research team from Johns Hopkins Medicine, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and ImmunoScape, a U.S.-Singapore

Immune Response 52

Immune Response Protein Medicine Genetics 52

pharmaphorum

JULY 12, 2022

The National Institutes of Health (NIH) is sponsoring the clinical trial of Moderna’s mRNA-1215 candidate, which will be carried out by scientists at the National Institute of Allergy and Infectious Diseases (NIAID). “The need for a preventive Nipah virus vaccine is significant,” he added. .

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

pharmaphorum

JULY 7, 2022

When COVID-19 first emerged, scientists cautioned that developing an effective and safe vaccine could take longer than the commonly estimated figure of a year. Once the pandemic hit, Moderna teamed up with the US National Institute of Allergy and Infectious Diseases (NIAID) to co-develop the former’s vaccine. Identifying the threat.

Vaccination 98

Vaccination Vaccine Development Research 98

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults.

Vaccination 53

Vaccination Vaccine Research Trials 53

Drug Discovery World

AUGUST 1, 2023

Dr Pirkko Muhonen, Senior Field Application Scientist, Nucleic Acid Therapeutics, at Thermo Fisher Scientific, shared what’s next for RNA-based medicine post-pandemic with DDW. This Phase I trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response.

RNA 52

RNA Drugs Gene Silencing Vaccination 52

Bioengineer

JULY 15, 2021

“We’re excited–with such low doses of radiation, we didn’t expect the response to be so positive,” said lead author Ravi Patel, M.D., In addition to the mouse studies, the physician-scientists worked together with David Vail, D.V.M.,

Medicine 52

Medicine Clinical Trials Clinical Trials Scientist 52

The Pharma Data

DECEMBER 29, 2020

The vaccine — which right now is known as NVX-CoV2373 — comes in two doses and is designed to enhance the body’s immune response to the coronavirus’ distinctive spike protein. National Institute of Allergy and Infectious Diseases, said last week. “They know someone who had a severe case or died.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

DECEMBER 31, 2020

National Institute of Allergy and Infectious Diseases, Gov. No evidence has been found that this variant is more deadly or causes more severe illness, and scientists are saying that the vaccines will be effective against it. Many scientists in the United States had assumed that the novel variant was already circulating among Americans.

Vaccination 52

Vaccination Vaccine Genetics Protein 52

XTalks

SEPTEMBER 14, 2020

These companies include Moderna, a US biotech company which has formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID), Oxford University who has partnered with AstraZeneca, and Johnson & Johnson, Merck and Pfizer. China’s COVID-19 Vaccine: Sinovac Biotech and CanSino Biologics.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92

pharmaphorum

JULY 26, 2022

AIDS was first identified in the US in 1981, but four decades later scientists are still learning exactly how the virus that causes the condition is structured and how the body reacts, or fails to react, once infected. The finding opens up the possibility of creating therapeutics that mimic the same response. Understanding the virus.

Gene Therapy 139

Gene Therapy Protein Vaccination Vaccine 139